Rep. Julie Johnson Sells Abbott Laboratories (NYSE:ABT) Shares

Representative Julie Johnson (D-Texas) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 18th. The trade occurred in the Representative’s “CHASE BROKERAGE ACCOUNT (3935)” account.

Representative Julie Johnson also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Texas Instruments (NASDAQ:TXN) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of UnitedHealth Group (NYSE:UNH) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of General Dynamics (NYSE:GD) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of PepsiCo (NASDAQ:PEP) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Dover (NYSE:DOV) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Philip Morris International (NYSE:PM) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Johnson & Johnson (NYSE:JNJ) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Bank of America (NYSE:BAC) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Walmart (NASDAQ:WMT) on 12/18/2025.
• Sold $1,001 – $15,000 in shares of Republic Services (NYSE:RSG) on 12/18/2025.

Abbott Laboratories Price Performance

ABT stock traded down $1.71 on Friday, reaching $121.82. The company had a trading volume of 10,338,220 shares, compared to its average volume of 5,209,277. The company’s fifty day moving average is $126.01 and its 200 day moving average is $128.95. The company has a market cap of $211.83 billion, a P/E ratio of 15.27, a PEG ratio of 2.02 and a beta of 0.72. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. Abbott Laboratories has a 1 year low of $113.39 and a 1 year high of $141.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.30. The business had revenue of $11.37 billion for the quarter, compared to the consensus estimate of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The business’s revenue was up 6.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.21 earnings per share. On average, research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.1%. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.59. Abbott Laboratories’s payout ratio is presently 31.58%.

Institutional Investors Weigh In On Abbott Laboratories

A number of institutional investors have recently added to or reduced their stakes in the company. IMG Wealth Management Inc. grew its holdings in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the period. Cloud Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter valued at approximately $29,000. Guerra Advisors Inc purchased a new stake in Abbott Laboratories during the third quarter worth approximately $31,000. Anfield Capital Management LLC increased its position in shares of Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares in the last quarter. Finally, Delos Wealth Advisors LLC purchased a new position in shares of Abbott Laboratories in the 2nd quarter valued at $32,000. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analyst Upgrades and Downgrades

ABT has been the topic of several analyst reports. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Abbott Laboratories in a research note on Monday, December 29th. Mizuho raised their target price on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. BTIG Research reaffirmed a “buy” rating and issued a $145.00 target price on shares of Abbott Laboratories in a research note on Thursday, November 20th. Sanford C. Bernstein increased their price target on Abbott Laboratories from $150.00 to $154.00 and gave the stock an “outperform” rating in a research note on Friday, January 9th. Finally, The Goldman Sachs Group lowered their price objective on Abbott Laboratories from $157.00 to $152.00 and set a “buy” rating for the company in a research report on Friday, January 9th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $147.42.

About Representative Johnson

Julie Johnson (Democratic Party) is a member of the U.S. House, representing Texas’ 32nd Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

Johnson (Democratic Party) ran for election to the U.S. House to represent Texas’ 32nd Congressional District. She won in the general election on November 5, 2024.

Julie Johnson earned a B.A. in history and government from the University of Texas at Austin in 1987 and a J.D. from the University of Houston Law Center in 1991. Johnson’s career experience includes working as an attorney.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.